LRRK2

Assets acting on this target.

Class
LRRK2 inhibitor

LRRK2 (leucine-rich repeat kinase 2) is a large, multidomain enzyme that combines kinase activity with a built-in GTPase switch, and it plays a central role in how cells manage internal trafficking, particularly the movement and maturation of lysosomes, the compartments that break down and recycle cellular waste. Certain inherited mutations in LRRK2 increase its kinase activity and are among the most common known genetic causes of Parkinson's disease, while elevated LRRK2 kinase activity has also been observed in some cases of Parkinson's disease without an identified genetic cause. This has made LRRK2 kinase activity a focal point for therapeutic modulation: by inhibiting the enzyme's catalytic function, it may be possible to restore more normal lysosomal and autophagic handling of proteins within neurons, including the clearance of aggregation-prone proteins implicated in Parkinson's pathology. Because this approach targets a proposed disease-driving process rather than only masking symptoms, it is being explored as a potential disease-modifying strategy rather than a purely symptomatic one. LRRK2 inhibitors are small molecules designed to block the enzyme's kinase activity, and their development reflects broader interest in intervening earlier in the neurodegenerative process that underlies Parkinson's disease and possibly related disorders of protein clearance.

By indication

Related mechanisms

LRRK2 drugs compared

4 drugs, stage by indication
4 drugs acting on LRRK2: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
BIIB122 / DNL151 (LRRK2 inhibitor)Biogen, Denali Therapeuticssmall moleculePhase 3Phase 3 in Parkinson's Disease
HT-4253Halia Therapeuticssmall moleculePhase 2Phase 2 in Alzheimer's Disease
NEU-411Neuron23small moleculePhase 2Phase 2 in Parkinson's Disease
ARV-102Arvinas Inc.protacPhase 1Not recorded

← all mechanisms